{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:31:31Z","timestamp":1790062291103,"version":"4.0.1"},"reference-count":288,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T00:00:00Z","timestamp":1552953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.00382","type":"journal-article","created":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T15:33:21Z","timestamp":1553009601000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":77,"title":["Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses"],"prefix":"10.3389","volume":"10","author":[{"given":"Silvia","family":"Menegatti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Rogge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,3,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3899\/jrheum.091461","article-title":"Epidemiology of immune-mediated inflammatory diseases: incidence, prevalence, natural history, and comorbidities","volume":"85","author":"El-Gabalawy","year":"2010","journal-title":"J Rheumatol Suppl."},{"key":"B2","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1146\/annurev-immunol-051116-052225","article-title":"Understanding human autoimmunity and autoinflammation through transcriptomics","volume":"35","author":"Banchereau","year":"2017","journal-title":"Annu Rev Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s10620-014-3350-9","article-title":"Environmental risk factors for inflammatory bowel diseases: a review","volume":"60","author":"Ananthakrishnan","year":"2015","journal-title":"Digest Dis Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S1474-4422(14)70267-4","article-title":"Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses","volume":"14","author":"Belbasis","year":"2015","journal-title":"Lancet Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nrg3502","article-title":"Genetic insights into common pathways and complex relationships among immune-mediated diseases","volume":"14","author":"Parkes","year":"2013","journal-title":"Nat Rev Genet."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e1002254","DOI":"10.1371\/journal.pgen.1002254","article-title":"Pervasive sharing of genetic effects in autoimmune disease","volume":"7","author":"Cotsapas","year":"2011","journal-title":"PLoS Genet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-immunol-051116-052442","article-title":"Genetics of infectious and inflammatory diseases: overlapping discoveries from association and exome-sequencing studies","volume":"35","author":"Langlais","year":"2017","journal-title":"Annu Rev Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/jhg.2015.99","article-title":"The genomic landscape of human immune-mediated diseases","volume":"60","author":"Wu","year":"2015","journal-title":"J Hum Genet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1038\/ng.2770","article-title":"Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis","volume":"45","author":"International","year":"2013","journal-title":"Nat Genet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature10251","article-title":"Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis","volume":"476","author":"International","year":"2011","journal-title":"Nature."},{"key":"B11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nature11582","article-title":"Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease","volume":"491","author":"Jostins","year":"2012","journal-title":"Nature."},{"key":"B12","first-page":"2667","article-title":"Inflammatory eye, skin, and bowel disease in spondyloarthritis: genetic, phenotypic, and environmental factors","volume":"28","author":"Brophy","year":"2001","journal-title":"J Rheumatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/01.ede.0000193605.93416.df","article-title":"Autoimmune diseases co-occurring within individuals and within families: a systematic review","volume":"17","author":"Somers","year":"2006","journal-title":"Epidemiology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nm.3260","article-title":"How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy","volume":"19","author":"Schett","year":"2013","journal-title":"Nat Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/312724a0","article-title":"Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin","volume":"312","author":"Pennica","year":"1984","journal-title":"Nature."},{"key":"B16","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0092-8674(01)00237-9","article-title":"The TNF and TNF receptor superfamilies: integrating mammalian biology","volume":"104","author":"Locksley","year":"2001","journal-title":"Cell."},{"key":"B17","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/nri1184","article-title":"Signalling pathways of the TNF superfamily: a double-edged sword","volume":"3","author":"Aggarwal","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"B18","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1128\/MCB.10.4.1498","article-title":"Regulation of tumor necrosis factor alpha transcription in macrophages: involvement of four kappa B-like motifs and of constitutive and inducible forms of NF-kappa B","volume":"10","author":"Collart","year":"1990","journal-title":"Mol Cell Biol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.1073\/pnas.83.11.3949","article-title":"Purification, characterization, and antitumor activity of nonrecombinant mouse tumor necrosis factor","volume":"83","author":"Haranaka","year":"1986","journal-title":"Proc Natl Acad Sci USA."},{"key":"B20","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/323338a0","article-title":"Identity of differentiation inducing factor and tumour necrosis factor","volume":"323","author":"Takeda","year":"1986","journal-title":"Nature."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1084\/jem.164.4.1206","article-title":"Tumor necrosis factor and lymphotoxin induce differentiation of human myeloid cell lines in synergy with immune interferon","volume":"164","author":"Trinchieri","year":"1986","journal-title":"J Exp Med."},{"key":"B22","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.4049\/jimmunol.139.9.2970","article-title":"Enhancement of human B cell proliferation and differentiation by tumor necrosis factor-alpha and interleukin 1","volume":"139","author":"Jelinek","year":"1987","journal-title":"J Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1084\/jem.166.3.786","article-title":"Effect of tumor necrosis factor alpha on mitogen-activated human B cells","volume":"166","author":"Kehrl","year":"1987","journal-title":"J Exp Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1084\/jem.163.6.1433","article-title":"Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1","volume":"163","author":"Dinarello","year":"1986","journal-title":"J Exp Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/1074-7613(95)90001-2","article-title":"Tumor necrosis factor-\u03b1 is required in the protective immune response against mycobacterium tuberculosis in mice","volume":"2","author":"Flynn","year":"1995","journal-title":"Immunity."},{"key":"B26","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.cytogfr.2014.07.016","article-title":"TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants - past, present and future","volume":"25","author":"Sedger","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"key":"B27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/0092-8674(88)90486-2","article-title":"A novel form of TNF\/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF","volume":"53","author":"Kriegler","year":"1988","journal-title":"Cell."},{"key":"B28","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/385733a0","article-title":"Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha","volume":"385","author":"Moss","year":"1997","journal-title":"Nature."},{"key":"B29","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/0092-8674(95)90192-2","article-title":"The transmembrane form of tumor-necrosis-factor is the prime activating ligand of the 80 Kda tumor-necrosis-factor receptor","volume":"83","author":"Grell","year":"1995","journal-title":"Cell."},{"key":"B30","doi-asserted-by":"publisher","first-page":"44155","DOI":"10.1074\/jbc.M207399200","article-title":"Control of receptor-induced signaling complex formation by the kinetics of ligand\/receptor interaction","volume":"277","author":"Krippner-Heidenreich","year":"2002","journal-title":"J Biol Chem."},{"key":"B31","doi-asserted-by":"publisher","first-page":"31906","DOI":"10.1074\/jbc.M105252200","article-title":"Genetic deletion of the tumor necrosis factor receptor p60 or p80 abrogates ligand-mediated activation of nuclear factor-kappa B and of mitogen-activated protein kinases in macrophages","volume":"276","author":"Mukhopadhyay","year":"2001","journal-title":"J Biol Chem."},{"key":"B32","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.4049\/jimmunol.161.6.3136","article-title":"TNFR80-dependent enhancement of TNFR60-induced cell death is mediated by TNFR-associated factor 2 and is specific for TNFR60","volume":"161","author":"Weiss","year":"1998","journal-title":"J Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.cellsig.2012.02.006","article-title":"Signal transduction by tumor necrosis factor receptors","volume":"24","author":"Cabal-Hierro","year":"2012","journal-title":"Cell Signal."},{"key":"B34","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrrheum.2015.169","article-title":"TNF biology, pathogenic mechanisms and emerging therapeutic strategies","volume":"12","author":"Kalliolias","year":"2016","journal-title":"Nat Rev Rheumatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nri3834","article-title":"Regulation of tumour necrosis factor signalling: live or let die","volume":"15","author":"Brenner","year":"2015","journal-title":"Nat Rev Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1126\/science.281.5383.1680","article-title":"NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation","volume":"281","author":"Wang","year":"1998","journal-title":"Science."},{"key":"B37","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.immuni.2004.08.017","article-title":"Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles","volume":"21","author":"Schneider-Brachert","year":"2004","journal-title":"Immunity."},{"key":"B38","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1146\/annurev-immunol-032414-112248","article-title":"Programmed necrosis in the cross talk of cell death and inflammation","volume":"33","author":"Chan","year":"2015","journal-title":"Annu Rev Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/nature14191","article-title":"Necroptosis and its role in inflammation","volume":"517","author":"Pasparakis","year":"2015","journal-title":"Nature."},{"key":"B40","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/nature11307","article-title":"TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis","volume":"488","author":"Gregory","year":"2012","journal-title":"Nature."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1084\/jem.172.4.1019","article-title":"Identification of a 60-kD tumor necrosis factor (TNF) receptor as the major signal transducing component in TNF responses","volume":"172","author":"Thoma","year":"1990","journal-title":"J Exp Med"},{"key":"B42","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.4049\/jimmunol.160.7.3152","article-title":"Overexpression of the p80 TNF receptor leads to TNF-dependent apoptosis, nuclear factor-kappa B activation, and c-Jun kinase activation","volume":"160","author":"Haridas","year":"1998","journal-title":"J Immunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/emboj\/16.5.1080","article-title":"Tumor necrosis factor alpha-induced activation of c-jun N-terminal kinase is mediated by TRAF2","volume":"16","author":"Reinhard","year":"1997","journal-title":"EMBO J."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1038\/sj.emboj.7600649","article-title":"TNF-alpha induced c-IAP1\/TRAF2 complex translocation to a Ubc6-containing compartment and TRAF2 ubiquitination","volume":"24","author":"Wu","year":"2005","journal-title":"EMBO J."},{"key":"B45","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1034\/j.1399-0039.1999.540608.x","article-title":"Polymorphic analysis of the high-affinity tumor necrosis factor receptor 2","volume":"54","author":"Pantelidis","year":"1999","journal-title":"Tissue Antigens."},{"key":"B46","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/1529-0131(200101)44:1<61::AID-ANR9>3.0.CO;2-Q","article-title":"Association between rheumatoid arthritis and polymorphism of tumor necrosis factor receptor II, but not tumor necrosis factor receptor I, in Caucasians","volume":"44","author":"Barton","year":"2001","journal-title":"Arthritis Rheumat."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1002\/art.10101","article-title":"Association between tumor necrosis factor receptor II and familial, but not sporadic, rheumatoid arthritis: evidence for genetic heterogeneity","volume":"46","author":"Dieude","year":"2002","journal-title":"Arthritis Rheumat."},{"key":"B48","doi-asserted-by":"publisher","first-page":"5994","DOI":"10.1074\/jbc.M411541200","article-title":"The Met-196 -> Arg variation of human tumor necrosis factor receptor 2 (TNFR2) affects TNF-alpha-induced apoptosis by impaired NF-kappaB signaling and target gene expression","volume":"280","author":"Till","year":"2005","journal-title":"J Biol Chem."},{"key":"B49","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/BF00257449","article-title":"Phase II clinical trial of high-dose recombinant human tumor necrosis factor","volume":"24","author":"Lenk","year":"1989","journal-title":"Cancer Chemother Pharmacol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1126\/science.3895437","article-title":"Passive immunization against cachectin\/tumor necrosis factor protects mice from lethal effect of endotoxin","volume":"229","author":"Beutler","year":"1985","journal-title":"Science."},{"key":"B51","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/330662a0","article-title":"Anti-cachectin\/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia","volume":"330","author":"Tracey","year":"1987","journal-title":"Nature"},{"key":"B52","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/nri802","article-title":"Development of anti-TNF therapy for rheumatoid arthritis","volume":"2","author":"Feldmann","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1002\/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E","article-title":"Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab","volume":"43","author":"Brandt","year":"2000","journal-title":"Arthritis Rheum"},{"key":"B54","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1136\/ard.61.suppl_3.iii51","article-title":"Anti-tumour necrosis factor \u03b1 therapy for ankylosing spondylitis: international experience","volume":"61","author":"Braun","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/NEJMoa012664","article-title":"Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha","volume":"346","author":"Gorman","year":"2002","journal-title":"N Engl J Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/art.39298","article-title":"American College of Rheumatology\/Spondylitis Association of America\/spondyloarthritis research and treatment network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"68","author":"Ward","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nrrheum.2016.42","article-title":"New evidence on the management of spondyloarthritis","volume":"12","author":"Sieper","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1136\/ard.62.9.829","article-title":"Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?","volume":"62","author":"Baeten","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"B59","doi-asserted-by":"publisher","first-page":"i472","DOI":"10.1136\/bmj.i472","article-title":"Rheumatoid arthritis, TNF inhibitors, and non-melanoma skin cancer","volume":"352","author":"Assassi","year":"2016","journal-title":"Bmj"},{"key":"B60","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1111\/jdv.12675","article-title":"An increased risk of non-melanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors","volume":"29","author":"van Lumig","year":"2015","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/path.1758","article-title":"Differential expression and response to anti-TNF\u03b1 treatment of infiltrating versus resident tissue macrophage subsets in autoimmune arthritis","volume":"206","author":"De Rycke","year":"2005","journal-title":"J Pathol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","article-title":"Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/0161-5890(93)90106-L","article-title":"Construction and initial characterization of a mouse-human chimeric anti-TNF antibody","volume":"30","author":"Knight","year":"1993","journal-title":"Mol Immunol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1006\/cyto.1995.1003","article-title":"The mouse\/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo","volume":"7","author":"Siegel","year":"1995","journal-title":"Cytokine."},{"key":"B65","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2217\/imt.10.34","article-title":"Golimumab as the first monthly subcutaneous fully human anti-TNF-alpha antibody in the treatment of inflammatory arthropathies","volume":"2","author":"Hutas","year":"2010","journal-title":"Immunotherapy."},{"key":"B66","doi-asserted-by":"publisher","first-page":"428","DOI":"10.4161\/mabs.12304","article-title":"Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha","volume":"2","author":"Shealy","year":"2010","journal-title":"mAbs"},{"key":"B67","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate","volume":"340","author":"Weinblatt","year":"1999","journal-title":"N Engl J Med."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1002\/ibd.20225","article-title":"Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor \u03b1 agents","volume":"13","author":"Nesbitt","year":"2007","journal-title":"Inflamm Bowel Dis."},{"key":"B69","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.clim.2009.01.002","article-title":"Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor","volume":"131","author":"Kaymakcalan","year":"2009","journal-title":"Clin Immunol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1053\/j.gastro.2004.01.036","article-title":"Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor-alpha","volume":"126","author":"Mitoma","year":"2004","journal-title":"Gastroenterology"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1016\/S0016-5085(03)00382-2","article-title":"Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease","volume":"124","author":"Van den Brande","year":"2003","journal-title":"Gastroenterology"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/art.23447","article-title":"Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor \u03b1-expressing cells: comparison among infliximab, etanercept, and adalimumab","volume":"58","author":"Mitoma","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1136\/annrheumdis-2011-150573","article-title":"A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry","volume":"71","author":"Greenberg","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"B74","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1186\/s13075-014-0467-3","article-title":"Efficacy and safety of pateclizumab (anti-lymphotoxin-alpha) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study)","volume":"16","author":"Kennedy","year":"2014","journal-title":"Arthritis Res Ther."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1136\/ard.2003.014878","article-title":"True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha?","volume":"63","author":"Buch","year":"2004","journal-title":"Ann Rheum Dis."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3315\/jdcr.2013.1126","article-title":"The risk of herpes zoster in the anti-TNF-alpha era: a case report and review of the literature","volume":"7","author":"Di Costanzo","year":"2013","journal-title":"J Dermatol Case Rep."},{"key":"B79","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1002\/art.24632","article-title":"Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry","volume":"60","author":"Tubach","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B81","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1093\/rheumatology\/ken094","article-title":"Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis","volume":"47","author":"Coates","year":"2008","journal-title":"Rheumatology."},{"key":"B82","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1006\/cyto.1995.0029","article-title":"Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions","volume":"7","author":"Scallon","year":"1995","journal-title":"Cytokine"},{"key":"B83","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol Ther."},{"key":"B84","doi-asserted-by":"publisher","first-page":"e12516","DOI":"10.1371\/journal.pone.0012516","article-title":"Linking power Doppler ultrasound to the presence of th17 cells in the rheumatoid arthritis joint","volume":"5","author":"Gullick","year":"2010","journal-title":"PLoS ONE"},{"key":"B85","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1093\/rheumatology\/keq224","article-title":"Increased IL-17 production by peripheral T helper cells after tumour necrosis factor blockade in rheumatoid arthritis is accompanied by inhibition of migration-associated chemokine receptor expression","volume":"49","author":"Aerts","year":"2010","journal-title":"Rheumatology"},{"key":"B86","doi-asserted-by":"publisher","first-page":"R126","DOI":"10.1186\/ar3431","article-title":"Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-\u03b1 therapy","volume":"13","author":"Chen","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1128\/CVI.00061-11","article-title":"Distinct effects of anti-tumor necrosis factor combined therapy on TH1\/TH2 balance in rheumatoid arthritis patients","volume":"18","author":"Herman","year":"2011","journal-title":"Clin Vacc Immunol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1007\/s10875-011-9542-6","article-title":"Combined treatment of etanercept and MTX reverses Th1\/Th2, Th17\/Treg imbalance in patients with rheumatoid arthritis","volume":"31","author":"Lina","year":"2011","journal-title":"J Clin Immunol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3899\/jrheum.110862","article-title":"In vivo peripheral blood proinflammatory T cells in patients with ankylosing spondylitis","volume":"39","author":"Lim\u00f3n-Camacho","year":"2012","journal-title":"J Rheumatol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1136\/annrheumdis-2011-201024","article-title":"Incomplete response of inflammatory arthritis to TNF\u03b1 blockade is associated with the Th17 pathway","volume":"71","author":"Alzabin","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"B91","doi-asserted-by":"publisher","first-page":"808724","DOI":"10.1155\/2012\/808724","article-title":"Adaptive immunity in ankylosing spondylitis: phenotype and functional alterations of T-cells before and during infliximab therapy","volume":"2012","author":"Szalay","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s10875-012-9774-0","article-title":"Levels of circulating Th17 cells and regulatory T cells in ankylosing spondylitis patients with an inadequate response to anti-TNF-\u03b1 therapy","volume":"33","author":"Xueyi","year":"2013","journal-title":"J Clin Immunol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s10067-013-2352-x","article-title":"The impact of conventional DMARD and biological therapies on CD4+ cell subsets in rheumatoid arthritis: a follow-up study","volume":"33","author":"Szalay","year":"2014","journal-title":"Clin. Rheumatol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1038\/ncomms4199","article-title":"TNF-alpha blockade induces IL-10 expression in human CD4+ T cells","volume":"5","author":"Evans","year":"2014","journal-title":"Nat Commun."},{"key":"B95","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/cei.12626","article-title":"Anti-tumour necrosis factor treatment increases circulating T helper type 17 cells similarly in different types of inflammatory arthritis","volume":"181","author":"Hull","year":"2015","journal-title":"Clin Exp Immunol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1007\/s10875-015-0182-0","article-title":"Paradoxical expansion of Th1 and Th17 lymphocytes in rheumatoid arthritis following infliximab treatment: a possible explanation for a lack of clinical response","volume":"35","author":"Talotta","year":"2015","journal-title":"J Clin Immunol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s13075-016-1197-5","article-title":"Increase in circulating Th17 cells during anti-TNF therapy is associated with ultrasonographic improvement of synovitis in rheumatoid arthritis","volume":"18","author":"Hull","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"B98","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1084\/jem.20040165","article-title":"Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy","volume":"200","author":"Ehrenstein","year":"2004","journal-title":"J Exp Med."},{"key":"B99","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1084\/jem.20061531","article-title":"Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta","volume":"204","author":"Nadkarni","year":"2007","journal-title":"J Exp Med."},{"key":"B100","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.cellimm.2012.09.001","article-title":"Anti-TNF-alpha therapy improves Treg and suppresses Teff in patients with rheumatoid arthritis","volume":"279","author":"Huang","year":"2012","journal-title":"Cell Immunol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1002\/art.34565","article-title":"Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy","volume":"64","author":"McGovern","year":"2012","journal-title":"Arthritis Rheumat"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1084\/jem.20151255","article-title":"Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF-TNF-RII binding in rheumatoid arthritis","volume":"213","author":"Nguyen","year":"2016","journal-title":"J Exp Med"},{"key":"B103","doi-asserted-by":"publisher","first-page":"688","DOI":"10.4049\/jimmunol.180.2.688","article-title":"Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks","volume":"180","author":"Anolik","year":"2008","journal-title":"J Immunol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"R84","DOI":"10.1186\/ar2718","article-title":"Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor","volume":"11","author":"Souto-Carneiro","year":"2009","journal-title":"Arthritis Res Ther."},{"key":"B105","doi-asserted-by":"publisher","first-page":"R209","DOI":"10.1186\/ar3542","article-title":"Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor","volume":"13","author":"Kobie","year":"2011","journal-title":"Arthritis Res Ther."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1136\/annrheumdis-2011-201270","article-title":"Anti-TNF treatment blocks the induction of T cell-dependent humoral responses","volume":"72","author":"Salinas","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B107","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/cei.12335","article-title":"Restoration of peripheral blood natural killer and B cell levels in patients affected by rheumatoid and psoriatic arthritis during etanercept treatment","volume":"177","author":"Conigliaro","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1002\/art.38666","article-title":"Regulatory B10 cells are decreased in patients with rheumatoid arthritis and are inversely correlated with disease activity","volume":"66","author":"Daien","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1002\/art.38736","article-title":"Distinct effects of methotrexate and etanercept on the B cell compartment in patients with juvenile idiopathic arthritis","volume":"66","author":"Glaesener","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"e0180726","DOI":"10.1371\/journal.pone.0180726","article-title":"Increased frequency of circulating CD19+CD24hiCD38hi B cells with regulatory capacity in patients with Ankylosing spondylitis (AS) na\u00efve for biological agents","volume":"12","author":"Bautista-Caro","year":"2017","journal-title":"PLoS ONE."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.vaccine.2016.01.027","article-title":"Diverse effects on vaccine-specific serum IgG titres and memory B cells upon methotrexate and anti-TNF-\u03b1 therapy in children with rheumatic diseases: a cross-sectional study","volume":"34","author":"Ingelman-Sundberg","year":"2016","journal-title":"Vaccine."},{"key":"B112","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1089\/dna.2015.3046","article-title":"Defective function of CD24(+)CD38(+) regulatory B cells in ankylosing spondylitis","volume":"35","author":"Chen","year":"2016","journal-title":"DNA Cell Biol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13075-017-1244-x","article-title":"Th17 and CD24hiCD27+ regulatory B lymphocytes are biomarkers of response to biologics in rheumatoid arthritis","volume":"19","author":"Salomon","year":"2017","journal-title":"Arthritis Res Ther."},{"key":"B114","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.clim.2017.05.012","article-title":"Regulatory B cells in rheumatoid arthritis: alterations in patients receiving anti-TNF therapy","volume":"184","author":"Banko","year":"2017","journal-title":"Clin Immunol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.clim.2017.04.010","article-title":"IL-10 producing Bregs are impaired in psoriatic arthritis and psoriasis and inversely correlate with IL-17- and IFNgamma-producing T cells","volume":"184","author":"Mavropoulos","year":"2017","journal-title":"Clin Immunol."},{"key":"B116","first-page":"31","article-title":"Influence of anti-tumor necrosis factor therapy (Adalimumab) on regulatory T cells and dendritic cells in rheumatoid arthritis","volume":"24","author":"Dombrecht","year":"2006","journal-title":"Clin Exp Rheumatol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jaut.2017.02.001","article-title":"Impact of anti-TNF therapy on NK cells function and on immunosurveillance against B-cell lymphomas","volume":"80","author":"Nocturne","year":"2017","journal-title":"J Autoimmunity"},{"key":"B118","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1136\/annrheumdis-2016-211069","article-title":"Chemotaxis of Vdelta2 T cells to the joints contributes to the pathogenesis of rheumatoid arthritis","volume":"76","author":"Mo","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B119","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/art.40736","article-title":"IL-22- and GM-CSF-expressing but not IL-17A-expressing group 3 innate lymphoid cells are expanded in the inflamed spondyloarthritis joint","volume":"71","author":"Blijdorp","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1002\/art.10545","article-title":"CD14+,CD16+ blood monocytes and joint inflammation in rheumatoid arthritis","volume":"46","author":"Kawanaka","year":"2002","journal-title":"Arthritis Rheumat."},{"key":"B121","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1365-2249.2012.04626.x","article-title":"Differential effects of infliximab on absolute circulating blood leucocyte counts of innate immune cells in early and late rheumatoid arthritis patients","volume":"170","author":"Coulthard","year":"2012","journal-title":"Clin Exp Immunol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"R139","DOI":"10.1186\/ar4321","article-title":"CD56+ monocytes have a dysregulated cytokine response to lipopolysaccharide and accumulate in rheumatoid arthritis and immunosenescence","volume":"15","author":"Krasselt","year":"2013","journal-title":"Arthritis Res Ther."},{"key":"B123","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.cyto.2014.03.004","article-title":"Interleukin-6 and tumour necrosis factor-alpha differentially regulate lincRNA transcripts in cells of the innate immune system in vivo in human subjects with rheumatoid arthritis","volume":"68","author":"Muller","year":"2014","journal-title":"Cytokine"},{"key":"B124","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s12967-015-0620-z","article-title":"In vitro response pattern of monocytes after tmTNF reverse signaling predicts response to anti-TNF therapy in rheumatoid arthritis","volume":"13","author":"Meusch","year":"2015","journal-title":"J Transl Med"},{"key":"B125","doi-asserted-by":"publisher","first-page":"e000079","DOI":"10.1136\/rmdopen-2015-000079","article-title":"Regulation of peripheral classical and non-classical monocytes on infliximab treatment in patients with rheumatoid arthritis and ankylosing spondylitis","volume":"2","author":"Aeberli","year":"2016","journal-title":"RMD Open."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1111\/apm.12757","article-title":"M2 polarization of monocytes in ankylosing spondylitis and relationship with inflammation and structural damage","volume":"125","author":"Zhao","year":"2017","journal-title":"Acta Pathol Microbiol Immunol Scand"},{"key":"B127","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1002\/1529-0131(199910)42:10<2166::AID-ANR18>3.0.CO;2-K","article-title":"Treatment with monoclonal anti-tumor necrosis factor alpha antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis","volume":"42","author":"Maurice","year":"1999","journal-title":"Arthritis Rheum"},{"key":"B128","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/art.10847","article-title":"Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab","volume":"48","author":"Zou","year":"2003","journal-title":"Arthritis Rheum"},{"key":"B129","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1136\/ard.62.6.561","article-title":"Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept","volume":"62","author":"Zou","year":"2003","journal-title":"Ann Rheumat Dis."},{"key":"B130","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/j.imbio.2011.07.006","article-title":"Anti-TNF therapy in patients with rheumatoid arthritis decreases Th1 and Th17 cell populations and expands IFN-gamma-producing NK cell and regulatory T cell subsets","volume":"216","author":"Aravena","year":"2011","journal-title":"Immunobiology"},{"key":"B131","doi-asserted-by":"publisher","first-page":"6894374","DOI":"10.1155\/2017\/6894374","article-title":"T-cell subsets in rheumatoid arthritis patients on long-term anti-TNF or IL-6 receptor blocker therapy","volume":"2017","author":"Dulic","year":"2017","journal-title":"Mediators Inflamm"},{"key":"B132","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.4049\/jimmunol.163.3.1521","article-title":"Regulation of cytokines, cytokine inhibitors, and acutephase proteins following anti-TNF-alpha therapy in rheumatoid arthritis","volume":"163","author":"Charles","year":"1999","journal-title":"J Immunol."},{"key":"B133","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/1529-0131(200001)43:1<38::AID-ANR6>3.0.CO;2-L","article-title":"Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis","volume":"43","author":"Taylor","year":"2000","journal-title":"Arthritis Rheumat"},{"key":"B134","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1136\/ard.60.7.660","article-title":"Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis","volume":"60","author":"Barrera","year":"2001","journal-title":"Ann Rheumat Dis"},{"key":"B135","first-page":"529","article-title":"Regulation of serum chemokines following infliximab therapy in patients with rheumatoid arthritis","volume":"24","author":"Klimiuk","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00296-007-0388-4","article-title":"Etanercept reduces the serum levels of interleukin-23 and macrophage inflammatory protein-3 alpha in patients with rheumatoid arthritis","volume":"28","author":"Kageyama","year":"2007","journal-title":"Rheumatol Int"},{"key":"B137","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1136\/ard.2006.066084","article-title":"Circulating levels of the chemokine CCL18 but not CXCL16 are elevated and correlate with disease activity in rheumatoid arthritis","volume":"66","author":"van Lieshout","year":"2007","journal-title":"Ann Rheum Dis."},{"key":"B138","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/j.1365-2249.2008.03691.x","article-title":"Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis","volume":"153","author":"Fabre","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"B139","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3899\/jrheum.090132","article-title":"Proinflammatory cytokines synergistically enhance the production of chemokine ligand 20 (CCL20) from rheumatoid fibroblast-like synovial cells in vitro and serum CCL20 is reduced in vivo by biologic disease-modifying antirheumatic drugs","volume":"36","author":"Kawashiri","year":"2009","journal-title":"J Rheumatol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.3899\/jrheum.081074","article-title":"Correlation of CX3CL1 and CX3CR1 levels with response to infliximab therapy in patients with rheumatoid arthritis","volume":"36","author":"Odai","year":"2009","journal-title":"J Rheumatol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1684\/ecn.2009.0150","article-title":"Cytokine production from stimulated whole blood cultures in rheumatoid arthritis patients treated with various TNF blocking agents","volume":"20","author":"Popa","year":"2009","journal-title":"Eur Cytokine Netw"},{"key":"B142","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.3899\/jrheum.091469","article-title":"Anti-tumor necrosis factor therapies reduce serum macrophage inflammatory protein-1alpha in ankylosing spondylitis","volume":"37","author":"Akbulut","year":"2010","journal-title":"J Rheumatol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s00296-009-1179-x","article-title":"The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17\/IL-6 secretion in rheumatoid arthritis patients","volume":"30","author":"Yue","year":"2010","journal-title":"Rheumatol Int"},{"key":"B144","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.clim.2011.01.015","article-title":"Dual role of anti-TNF therapy: enhancement of TCR-mediated T cell activation in peripheral blood and inhibition of inflammation in target tissues","volume":"139","author":"Bos\u00e8","year":"2011","journal-title":"Clin Immunol"},{"key":"B145","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/1471-2474-13-191","article-title":"Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis","volume":"13","author":"Taylan","year":"2012","journal-title":"BMC Musculoskelet Disorders."},{"key":"B146","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1093\/rheumatology\/kes094","article-title":"Interleukin-1beta measurement in stimulated whole blood cultures is useful to predict response to anti-TNF therapies in rheumatoid arthritis","volume":"51","author":"Kayakabe","year":"2012","journal-title":"Rheumatology"},{"key":"B147","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1089\/jir.2012.0122","article-title":"Elevated serum and synovial fluid levels of interleukin-34 in rheumatoid arthritis: possible association with disease progression via interleukin-17 production","volume":"33","author":"Tian","year":"2013","journal-title":"J Interfer Cytokine Res."},{"key":"B148","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1186\/s13075-014-0434-z","article-title":"CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic \u2018window of opportunity\u2019","volume":"16","author":"Greisen","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"B149","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00296-014-3056-5","article-title":"Baseline serum interleukin-34 levels independently predict radiographic progression in patients with rheumatoid arthritis","volume":"35","author":"Chang","year":"2015","journal-title":"Rheumatol Int."},{"key":"B150","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1007\/s00296-015-3314-1","article-title":"Anti-TNF-alpha therapy reduces endothelial cell activation in non-diabetic ankylosing spondylitis patients","volume":"35","author":"Genre","year":"2015","journal-title":"Rheumatol Int."},{"key":"B151","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13075-016-0949-6","article-title":"IL-23\/Th17 axis is not influenced by TNF-blocking agents in ankylosing spondylitis patients","volume":"18","author":"Milanez","year":"2016","journal-title":"Arthritis Res Ther."},{"key":"B152","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-016-0995-0","article-title":"Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study","volume":"10","author":"Han","year":"2016","journal-title":"Arthritis Res Ther."},{"key":"B153","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/cei.12782","article-title":"The impact of disease activity and tumour necrosis factor-alpha inhibitor therapy on cytokine levels in juvenile idiopathic arthritis","volume":"184","author":"Walters","year":"2016","journal-title":"Clin Exp Immunol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1136\/annrheumdis-2015-208001","article-title":"Increased pretreatment serum IFN-\u03b2\/a ratio predicts nonresponse to tumour necrosis factor a inhibition in rheumatoid arthritis","volume":"75","author":"Wampler Muskardin","year":"2016","journal-title":"Ann Rheumat Dis."},{"key":"B155","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s12016-017-8610-y","article-title":"Response to treatment with TNFa inhibitors in rheumatoid arthritis is associated with high levels of GM-CSF and GM-CSF+ T lymphocytes","volume":"53","author":"Bystrom","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"B156","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-01771-2","article-title":"Unique transcriptome signatures and GM-CSF expression in lymphocytes from patients with spondyloarthritis","volume":"8","author":"Al-Mossawi","year":"2017","journal-title":"Nat Commun"},{"key":"B157","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.3389\/fimmu.2017.01967","article-title":"Increased frequency of peripheral B and T cells expressing granulocyte monocyte colony-stimulating factor in rheumatoid arthritis patients","volume":"8","author":"Makris","year":"2017","journal-title":"Front Immunol"},{"key":"B158","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.cyto.2016.09.001","article-title":"TNF\u03b1 in the regulation of Treg and Th17 cells in rheumatoid arthritis and other autoimmune inflammatory diseases","volume":"101","author":"Bystrom","year":"2018","journal-title":"Cytokine"},{"key":"B159","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s13075-018-1725-6","article-title":"Modulation of T-cell responses by anti-tumor necrosis factor treatments in rheumatoid arthritis: a review","volume":"20","author":"Davignon","year":"2018","journal-title":"Arthritis Res Ther."},{"key":"B160","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1084\/jem.185.9.1573","article-title":"Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling","volume":"185","author":"Cope","year":"1997","journal-title":"J Exp Med"},{"key":"B161","doi-asserted-by":"publisher","first-page":"4328","DOI":"10.1182\/blood-2006-12-064170","article-title":"TCRzetadim lymphocytes define populations of circulating effector cells that migrate to inflamed tissues","volume":"109","author":"Zhang","year":"2007","journal-title":"Blood"},{"key":"B162","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/nm1551","article-title":"A brief history of TH17, the first major revision in the TH1\/TH2 hypothesis of T cell\u2013mediated tissue damage","volume":"13","author":"Steinman","year":"2007","journal-title":"Nat Med"},{"key":"B163","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1002\/eji.200838411","article-title":"Exogenous IFN-gamma ex vivo shapes the alloreactive T-cell repertoire by inhibition of Th17 responses and generation of functional Foxp3+ regulatory T cells","volume":"38","author":"Feng","year":"2008","journal-title":"Eur J Immunol"},{"key":"B164","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/ni1254","article-title":"Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages","volume":"6","author":"Harrington","year":"2005","journal-title":"Nat Immunol"},{"key":"B165","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/art.22453","article-title":"Interferon-gamma regulates susceptibility to collagen-induced arthritis through suppression of interleukin-17","volume":"56","author":"Chu","year":"2007","journal-title":"Arthritis Rheum"},{"key":"B166","doi-asserted-by":"publisher","first-page":"R122","DOI":"10.1186\/ar2787","article-title":"Effector mechanisms of interleukin-17 in collagen-induced arthritis in the absence of interferon-gamma and counteraction by interferon-gamma","volume":"11","author":"Kelchtermans","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"B167","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1136\/ard.2003.008599","article-title":"Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis","volume":"63","author":"Nissinen","year":"2004","journal-title":"Ann Rheum. Dis."},{"key":"B168","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1093\/rheumatology\/keg171","article-title":"Influence of therapy with chimeric monoclonal tumour necrosis factor-alpha antibodies on intracellular cytokine profiles of T lymphocytes and monocytes in rheumatoid arthritis patients","volume":"42","author":"Schuerwegh","year":"2003","journal-title":"Rheumatology."},{"key":"B169","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1084\/jem.20072707","article-title":"Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells","volume":"205","author":"Notley","year":"2008","journal-title":"J Exp Med."},{"key":"B170","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/art.23269","article-title":"Plasminogen activator\/plasmin system in arthritis and inflammation: friend or foe?","volume":"58","author":"Hamilton","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B171","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/s40674-018-0095-1","article-title":"Novel therapeutic targets in axial spondyloarthritis","volume":"4","author":"Worth","year":"2018","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"B172","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/stem.5530080705","article-title":"The biology of GM-CSF: regulation of production and interaction with its receptor","volume":"8","author":"Griffin","year":"1990","journal-title":"Int J Cell Cloning"},{"key":"B173","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1136\/annrheumdis-2014-206578","article-title":"Synovial CD4+ T-cell-derived GM-CSF supports the differentiation of an inflammatory dendritic cell population in rheumatoid arthritis","volume":"75","author":"Reynolds","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B174","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1136\/annrheumdis-2014-205234","article-title":"Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis","volume":"74","author":"Greven","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B175","doi-asserted-by":"publisher","first-page":"e000487","DOI":"10.1136\/rmdopen-2017-000487","article-title":"Th1 is the predominant helper T cell subset that produces GM-CSF in the joint of rheumatoid arthritis","volume":"3","author":"Yamada","year":"2017","journal-title":"RMD Open."},{"key":"B176","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/art.40420","article-title":"Mavrilimumab, a fully human granulocyte-macrophage colony-stimulating factor receptor \u03b1 monoclonal antibody: long-term safety and efficacy in patients with rheumatoid arthritis","volume":"70","author":"Burmester","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"B177","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/art.1780390702","article-title":"Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis","volume":"39","author":"Tak","year":"1996","journal-title":"Arthritis Rheum"},{"key":"B178","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/10408360091174187","article-title":"Measurement of cytokines in clinical samples using immunoassays: problems and pitfalls","volume":"37","author":"Banks","year":"2000","journal-title":"Crit Rev Clin Lab Sci."},{"key":"B179","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1093\/rheumatology\/keh437","article-title":"Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors","volume":"44","author":"Aeberli","year":"2005","journal-title":"Rheumatology"},{"key":"B180","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1084\/jem.20071397","article-title":"Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model","volume":"204","author":"Hirota","year":"2007","journal-title":"J Exp Med"},{"key":"B181","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.cytogfr.2005.04.007","article-title":"CXC chemokines in angiogenesis","volume":"16","author":"Strieter","year":"2005","journal-title":"Cytokine Growth Factor Rev."},{"key":"B182","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s00296-007-0317-6","article-title":"Synovial angiostatic non-ELR CXC chemokines in inflammatory arthritides: does CXCL4 designate chronicity of synovitis?","volume":"27","author":"Erdem","year":"2007","journal-title":"Rheumatol Int."},{"key":"B183","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13075-017-1337-6","article-title":"Chemokine signals are crucial for enhanced homing and differentiation of circulating osteoclast progenitor cells","volume":"19","author":"Sucur","year":"2017","journal-title":"Arthritis Res Ther."},{"key":"B184","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/cei.12900","article-title":"Gut microbiome in children with enthesitis-related arthritis in a developing country and the effect of probiotic administration","volume":"187","author":"Aggarwal","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"B185","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.clinthera.2018.04.016","article-title":"B Lymphocytes in rheumatoid arthritis and the effects of anti-TNF-\u03b1 agents on B lymphocytes: a review of the literature","volume":"40","author":"Pala","year":"2018","journal-title":"Clin Ther."},{"key":"B186","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3389\/fimmu.2012.00302","article-title":"Advances in human B cell phenotypic profiling","volume":"3","author":"Kaminski","year":"2012","journal-title":"Front Immunol."},{"key":"B187","doi-asserted-by":"publisher","first-page":"e107086","DOI":"10.1371\/journal.pone.0107086","article-title":"Decreased frequencies of circulating follicular helper T cell counterparts and plasmablasts in ankylosing spondylitis patients Na\u00efve for TNF blockers","volume":"9","author":"Bautista-Caro","year":"2014","journal-title":"PLoS ONE"},{"key":"B188","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jaut.2007.07.002","article-title":"Disturbances in B- and T-cell homeostasis in rheumatoid arthritis: suggested relationships with antigen-driven immune responses","volume":"29","author":"Fekete","year":"2007","journal-title":"J Autoimmun."},{"key":"B189","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1093\/intimm\/dxv038","article-title":"The expanding family of regulatory B cells","volume":"27","author":"Mauri","year":"2015","journal-title":"Int Immunol"},{"key":"B190","doi-asserted-by":"publisher","first-page":"173ra23","DOI":"10.1126\/scitranslmed.3005407","article-title":"CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation","volume":"5","author":"Flores-Borja","year":"2013","journal-title":"Sci Transl Med."},{"key":"B191","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.cyto.2008.11.008","article-title":"Differences in binding and effector functions between classes of TNF antagonists","volume":"45","author":"Arora","year":"2009","journal-title":"Cytokine."},{"key":"B192","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.clim.2009.09.014","article-title":"Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers: safety and immunogenicity","volume":"134","author":"Salemi","year":"2010","journal-title":"Clin Immunol"},{"key":"B193","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nrrheum.2016.217","article-title":"Ectopic lymphoid neogenesis in rheumatic autoimmune diseases","volume":"13","author":"Bombardieri","year":"2017","journal-title":"Rheumatology."},{"key":"B194","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3389\/fimmu.2016.00430","article-title":"Ectopic lymphoid structures: powerhouse of autoimmunity","volume":"7","author":"Corsiero","year":"2016","journal-title":"Front Immunol."},{"key":"B195","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1084\/jem.20021761","article-title":"Ectopic LT alpha beta directs lymphoid organ neogenesis with concomitant expression of peripheral node addressin and a HEV-restricted sulfotransferase","volume":"197","author":"Drayton","year":"2003","journal-title":"J Exp Med."},{"key":"B196","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/mi.2013.79","article-title":"TNFalpha-dependent development of lymphoid tissue in the absence of RORgammat(+) lymphoid tissue inducer cells","volume":"7","author":"Furtado","year":"2014","journal-title":"Mucos Immunol."},{"key":"B197","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1084\/jem.183.4.1461","article-title":"Chronic inflammation caused by lymphotoxin is lymphoid neogenesis","volume":"183","author":"Kratz","year":"1996","journal-title":"J Exp Med."},{"key":"B198","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1136\/ard.2008.089284","article-title":"Clinical significance of synovial lymphoid neogenesis and its reversal after anti-tumour necrosis factor alpha therapy in rheumatoid arthritis","volume":"68","author":"Canete","year":"2009","journal-title":"Ann Rheumat Dis."},{"key":"B199","doi-asserted-by":"publisher","first-page":"785","DOI":"10.4049\/jimmunol.181.1.785","article-title":"B lymphocyte autoimmunity in rheumatoid synovitis is independent of ectopic lymphoid neogenesis","volume":"181","author":"Cantaert","year":"2008","journal-title":"J Immunol."},{"key":"B200","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/imm.12554","article-title":"Ectopic lymphoid follicles: inducible centres for generating antigen-specific immune responses within tissues","volume":"147","author":"Jones","year":"2016","journal-title":"Immunology."},{"key":"B201","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1371\/journal.pmed.0060001","article-title":"Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium","volume":"6","author":"Humby","year":"2009","journal-title":"PLoS Med."},{"key":"B202","doi-asserted-by":"publisher","first-page":"316421","DOI":"10.1155\/2015\/316421","article-title":"Ectopic germinal centers and IgG4-producing plasmacytes observed in synovia of HLA-B27+ ankylosing spondylitis patients with advanced hip involvement","volume":"2015","author":"Feng","year":"2015","journal-title":"Int J Rheumatol."},{"key":"B203","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1136\/ard.2003.016386","article-title":"Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis","volume":"63","author":"Rudwaleit","year":"2004","journal-title":"Ann Rheum Dis."},{"key":"B204","doi-asserted-by":"publisher","first-page":"R94","DOI":"10.1186\/ar3369","article-title":"Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study","volume":"13","author":"Arends","year":"2011","journal-title":"Arthritis Res Ther."},{"key":"B205","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1002\/art.24838","article-title":"Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis","volume":"61","author":"de Vries","year":"2009","journal-title":"Arthritis Rheumat."},{"key":"B206","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.reuma.2013.12.006","article-title":"ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy","volume":"10","author":"Vastesaeger","year":"2014","journal-title":"Reumatol Clin."},{"key":"B207","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1093\/rheumatology\/ket433","article-title":"Body weight, gender and response to TNF-\u03b1 blockers in axial spondyloarthritis","volume":"53","author":"Gremese","year":"2014","journal-title":"Rheumatology."},{"key":"B208","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1093\/rheumatology\/kev392","article-title":"Impact of tobacco smoking on response to tumour necrosis factor-alpha inhibitor treatment in patients with ankylosing spondylitis: results from the Danish nationwide DANBIO registry","volume":"55","author":"Glintborg","year":"2016","journal-title":"Rheumatology."},{"key":"B209","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1136\/ard.2010.138883","article-title":"ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFalpha inhibitors","volume":"70","author":"Pedersen","year":"2011","journal-title":"Ann Rheumat Dis."},{"key":"B210","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1186\/s13075-014-0413-4","article-title":"Calprotectin (S100A8\/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis","volume":"16","author":"Turina","year":"2014","journal-title":"Arthritis Res Ther."},{"key":"B211","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2013-203923","article-title":"MRP8\/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis","volume":"74","author":"Choi","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"B212","doi-asserted-by":"publisher","first-page":"R11","DOI":"10.1186\/ar2912","article-title":"Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment","volume":"12","author":"van Baarsen","year":"2010","journal-title":"Arthritis Res Ther."},{"key":"B213","doi-asserted-by":"publisher","first-page":"R50","DOI":"10.1186\/ar2419","article-title":"Molecular discrimination of responders and nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept","volume":"10","author":"Koczan","year":"2008","journal-title":"Arthritis Res Ther."},{"key":"B214","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/clpt.2009.244","article-title":"CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis","volume":"87","author":"Stuhlm\u00fcller","year":"2010","journal-title":"Clin Pharmacol Ther."},{"key":"B215","first-page":"1","article-title":"Cell-centred meta-analysis reveals baseline predictors of anti-TNF\u03b1 non-response in biopsy and blood of patients with IB","volume":"2018","author":"Gaujoux","year":"2018","journal-title":"Gut"},{"key":"B216","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nm.4307","article-title":"Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease","volume":"23","author":"West","year":"2017","journal-title":"Nat Med."},{"key":"B217","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nm.3462","article-title":"In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease","volume":"20","author":"Atreya","year":"2014","journal-title":"Nat Med."},{"key":"B218","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.1038\/s41598-018-23571-4","article-title":"Microbiota composition may predict anti-Tnf alpha response in spondyloarthritis patients: an exploratory study","volume":"8","author":"Bazin","year":"2018","journal-title":"Sci Rep."},{"key":"B219","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1002\/art.37921","article-title":"Metabolic profiling predicts response to anti-tumor necrosis factor \u03b1 therapy in patients with rheumatoid arthritis","volume":"65","author":"Kapoor","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B220","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"B221","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/ard.2010.138594","article-title":"Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores","volume":"70","author":"Machado","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B222","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/nrrheum.2013.93","article-title":"Spondyloarthritis: is it time to replace BASDAI with ASDAS?","volume":"9","author":"Machado","year":"2013","journal-title":"Nat Rev Rheumatol."},{"key":"B223","first-page":"980","article-title":"Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis","volume":"26","author":"Spoorenberg","year":"1999","journal-title":"J Rheumatol."},{"key":"B224","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1056\/NEJM199902113400607","article-title":"Acute-phase proteins and other systemic responses to inflammation","volume":"340","author":"Gabay","year":"1999","journal-title":"N Engl J Med."},{"key":"B225","first-page":"966","article-title":"Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review","volume":"26","author":"Ruof","year":"1999","journal-title":"J Rheumatol."},{"key":"B226","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1136\/ard.2010.147744","article-title":"Predicting the outcome of ankylosing spondylitis therapy","volume":"70","author":"Vastesaeger","year":"2011","journal-title":"Ann Rheumat Dis."},{"key":"B227","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1093\/rheumatology\/kel149","article-title":"Predictors of response to anti-TNF-\u03b1 therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register","volume":"45","author":"Hyrich","year":"2006","journal-title":"Rheumatology."},{"key":"B228","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.3899\/jrheum.101128","article-title":"Serum MMP-3 level as a biomarker for monitoring and predicting response to etanercept treatment in ankylosing spondylitis","volume":"38","author":"Arends","year":"2011","journal-title":"J Rheumatol."},{"key":"B229","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1136\/annrheumdis-2014-205506","article-title":"Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis","volume":"73","author":"Turina","year":"2014","journal-title":"Ann Rheumat Dis."},{"key":"B230","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1128\/MCB.23.7.2564-2576.2003","article-title":"Identification of fungi with potential micotoxigenic in fish meals used for preparation","volume":"23","author":"Hobbs","year":"2003","journal-title":"Mol Cell Biol."},{"key":"B231","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.jmb.2006.04.009","article-title":"Calcium-dependent tetramer formation of S100A8 and S100A9 is essential for biological activity","volume":"359","author":"Leukert","year":"2006","journal-title":"J Mol Biol."},{"key":"B232","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.1002\/art.20631","article-title":"Proinflammatory S100 proteins in arthritis and autoimmune disease","volume":"50","author":"Foell","year":"2004","journal-title":"Arthritis Rheumat."},{"key":"B233","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1136\/ard.2007.077800","article-title":"Myeloid-related proteins S100A8\/S100A9 regulate joint inflammation and cartilage destruction during antigen-induced arthritis","volume":"67","author":"Van Lent","year":"2008","journal-title":"Ann rheumat Dis."},{"key":"B234","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/nm1638","article-title":"Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock","volume":"13","author":"Vogl","year":"2007","journal-title":"Nat Med."},{"key":"B235","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/nm.2150","article-title":"The toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+T cells","volume":"16","author":"Loser","year":"2010","journal-title":"Nat Med."},{"key":"B236","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheumat Dis."},{"key":"B237","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nrrheum.2015.83","article-title":"Rheumatoid arthritis: biomarkers of response to TNF inhibition in RA","volume":"11","author":"Ranganathan","year":"2015","journal-title":"Nat Rev Rheumatol."},{"key":"B238","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1002\/art.27457","article-title":"Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy","volume":"62","author":"Cui","year":"2010","journal-title":"Arthritis Rheumat."},{"key":"B239","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/art.33381","article-title":"Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort","volume":"64","author":"Plant","year":"2012","journal-title":"Arthritis Rheumat."},{"key":"B240","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10753-012-9544-4","article-title":"Association of rheumatoid arthritis risk alleles with response to anti-TNF biologics: results from the CORRONA registry and meta-analysis","volume":"36","author":"Pappas","year":"2013","journal-title":"Inflammation."},{"key":"B241","doi-asserted-by":"publisher","first-page":"e1003394","DOI":"10.1371\/journal.pgen.1003394","article-title":"Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis","volume":"9","author":"Cui","year":"2013","journal-title":"PLoS Genet."},{"key":"B242","doi-asserted-by":"publisher","first-page":"12460","DOI":"10.1038\/ncomms12460","article-title":"Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis","volume":"7","author":"Sieberts","year":"2016","journal-title":"Nat Commun."},{"key":"B243","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1074\/jbc.M207577200","article-title":"Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17","volume":"278","author":"Aggarwal","year":"2003","journal-title":"J Biol Chem."},{"key":"B244","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/nature01355","article-title":"Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain","volume":"421","author":"Cua","year":"2003","journal-title":"Nature."},{"key":"B245","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1084\/jem.20041257","article-title":"IL-23 drives a pathogenic T cell population that induces autoimmune inflammation","volume":"201","author":"Langrish","year":"2005","journal-title":"J Exp Med"},{"key":"B246","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/ni.1698","article-title":"The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo","volume":"10","author":"McGeachy","year":"2009","journal-title":"Nat Immunol."},{"key":"B247","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/nature08949","article-title":"Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology","volume":"464","author":"Buonocore","year":"2010","journal-title":"Nature"},{"key":"B248","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1084\/jem.20101712","article-title":"IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease","volume":"208","author":"Geremia","year":"2011","journal-title":"J Exp Med"},{"key":"B249","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.immuni.2009.08.001","article-title":"Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity","volume":"31","author":"Sutton","year":"2009","journal-title":"Immunity"},{"key":"B250","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1002\/art.33507","article-title":"Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive gamma\/delta T cells in patients with active ankylosing spondylitis","volume":"64","author":"Kenna","year":"2012","journal-title":"Arthritis Rheum."},{"key":"B251","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-gammat(+) CD3(+)CD4(-)CD8(-) entheseal resident T cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat Med."},{"key":"B252","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrrheum.2015.133","article-title":"Genetics of ankylosing spondylitis-insights into pathogenesis","volume":"12","author":"Brown","year":"2016","journal-title":"Nat Rev Rheumatol."},{"key":"B253","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1002\/art.37936","article-title":"Combinatorial control of Th17 and Th1 cell functions by genetic variations in genes associated with the interleukin-23 signaling pathway in spondyloarthritis","volume":"65","author":"Coffre","year":"2013","journal-title":"Arthritis Rheum."},{"key":"B254","doi-asserted-by":"publisher","first-page":"e17160","DOI":"10.1371\/journal.pone.0017160","article-title":"The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans","volume":"6","author":"Di Meglio","year":"2011","journal-title":"PLoS ONE"},{"key":"B255","doi-asserted-by":"publisher","first-page":"9560","DOI":"10.1073\/pnas.1017854108","article-title":"Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+ and CD8+ human T-cell functional responses","volume":"108","author":"Sarin","year":"2011","journal-title":"Proc Natl Acad Sci USA."},{"key":"B256","doi-asserted-by":"publisher","first-page":"1246949","DOI":"10.1126\/science.1246949","article-title":"Innate immune activity conditions the effect of regulatory variants upon monocyte gene expression","volume":"343","author":"Fairfax","year":"2014","journal-title":"Science"},{"key":"B257","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13073-014-0092-4","article-title":"Approaches for establishing the function of regulatory genetic variants involved in disease","volume":"6","author":"Knight","year":"2014","journal-title":"Genome Med."},{"key":"B258","doi-asserted-by":"publisher","first-page":"E488","DOI":"10.1073\/pnas.1714765115","article-title":"Distinctive roles of age, sex, and genetics in shaping transcriptional variation of human immune responses to microbial challenges","volume":"115","author":"Piasecka","year":"2018","journal-title":"Proc Natl Acad Sci USA."},{"key":"B259","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1146\/annurev-med-051914-021944","article-title":"Therapeutic targeting of IL-17 and IL-23 cytokines in immune-mediated diseases","volume":"67","author":"Fragoulis","year":"2016","journal-title":"Annu Rev Med."},{"key":"B260","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1002\/art.23655","article-title":"Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides","volume":"58","author":"Jandus","year":"2008","journal-title":"Arthritis Rheum."},{"key":"B261","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1002\/art.24568","article-title":"Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis","volume":"60","author":"Shen","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B262","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.4049\/jimmunol.1002653","article-title":"Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis","volume":"186","author":"Bowness","year":"2011","journal-title":"J Immunol."},{"key":"B263","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","article-title":"Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Baeten","year":"2013","journal-title":"Lancet"},{"key":"B264","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med."},{"key":"B265","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B266","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2013results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med."},{"key":"B267","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"B268","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med."},{"key":"B269","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab in Crohn's Disease Study, Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"B270","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/ajg.2016.298","article-title":"A randomized, Double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe crohn's disease","volume":"111","author":"Targan","year":"2016","journal-title":"Am J Gastroenterol."},{"key":"B271","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.immuni.2015.09.003","article-title":"Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability","volume":"43","author":"Lee","year":"2015","journal-title":"Immunity"},{"key":"B272","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1002\/art.40581","article-title":"Brief report: interleukin-17 blockade with secukinumab in peripheral spondyloarthritis impacts synovial Immunopathology without compromising systemic immune responses","volume":"70","author":"van Mens","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"B273","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJMoa062382","article-title":"A human interleukin-12\/23 monoclonal antibody for the treatment of psoriasis","volume":"356","author":"Krueger","year":"2007","journal-title":"N Engl J Med."},{"key":"B274","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"B275","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"B276","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N Engl J Med."},{"key":"B277","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N Engl J Med."},{"key":"B278","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1084\/jem.20030896","article-title":"Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation","volume":"198","author":"Murphy","year":"2003","journal-title":"J Exp Med."},{"key":"B279","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1084\/jem.20061099","article-title":"Interleukin-23 drives innate and T cell-mediated intestinal inflammation","volume":"203","author":"Hue","year":"2006","journal-title":"J Exp Med"},{"key":"B280","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1172\/JCI21404","article-title":"IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6","volume":"116","author":"Yen","year":"2006","journal-title":"J Clin Invest."},{"key":"B281","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/S0140-6736(17)30570-6","article-title":"Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study","volume":"389","author":"Feagan","year":"2017","journal-title":"Lancet"},{"key":"B282","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med."},{"key":"B283","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"B284","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1038\/ng.2007.17","article-title":"Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants","volume":"39","author":"Burton","year":"2007","journal-title":"Nat Genet."},{"key":"B285","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/ng.3528","article-title":"Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci","volume":"48","author":"Ellinghaus","year":"2016","journal-title":"Nat. Genet."},{"key":"B286","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/ng.2667","article-title":"Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci","volume":"45","author":"International","year":"2013","journal-title":"Nat. Genet."},{"key":"B287","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1136\/annrheumdis-2015-208902","article-title":"IL-7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis","volume":"75","author":"Gracey","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"B288","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.3389\/fimmu.2018.01550","article-title":"The initiation, but not the persistence, of experimental spondyloarthritis is dependent on interleukin-23 signaling","volume":"9","author":"van Tok","year":"2018","journal-title":"Front Immunol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.00382\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T17:19:46Z","timestamp":1694711986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.00382\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,19]]},"references-count":288,"alternative-id":["10.3389\/fimmu.2019.00382"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.00382","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,19]]},"article-number":"382"}}